EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer

Sa Deok Hong iD, Nar Bahadur Katuwal iD, Min Sil Kang iD, Mithun Ghosh, Seong Min Park, Tae Hoen Kim, Young Seok Baek, Seung Ryeol Lee iD, Yong Wha Moon iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252111733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sa Deok Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, The Graduate School, CHA University, Seongnam-si 13488, Republic of Korea. Hauptthemen laut MEDLINE: Killer Cells, Natural, Trastuzumab, Antibody-Dependent Cell Cytotoxicity, Ovarian Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is the deadliest gynecologic cancer. Although human epidermal growth factor receptor-2 (HER2) overexpression, a poor prognostic molecular marker in ovarian cancer, is found in almost 30% of ovarian cancer cases, there are no established therapies for HER2-overexpressing ovarian cancer. In this study, we investigated the efficacy of combined samfenet, a biosimilar compound of trastuzumab, and natural killer (NK) cells in preclinical model of HER2-overexpressing ovarian cancer. Firstly, we screened the HER2 expression in three ovarian cancer cell lines and eight ovarian cancer patient-derived tumor xenograft (PDTX) samples. Then, immunohistochemistry and silver in situ hybridization (SISH) were performed following clinical criteria. HER2-overexpressing cells exhibited the highest sensitivity to samfenet compared with low-HER2-expressing cells. In addition, the combination of samfenet with natural killer (NK) cells resulted in significantly enhanced sensitivity to HER2-overexpressing cells and showed a significant antitumor effect on PDTX mice compared with monotherapy. It is known that anti-HER2-humanized IgG1 monoclonal antibodies, including trastuzumab, induce antibody-dependent cellular cytotoxicity (ADCC). Consequently, the combination of samfenet with NK cells demonstrated NK cell-mediated ADCC, as confirmed using an in vitro NK cytotoxicity assay and in vivo antitumor efficacy. A transferase dUTP nick end labeling (TUNEL) assay using xenografted tumors further supported the ADCC effects based on the increase in the number of apoptotic cells in the combination group. Furthermore, high HER2 expression was associated with shorter progression-free survival and overall survival based on public mRNA expression data. In this study, we demonstrated that the combination of samfenet and NK cell therapy could be a promising treatment strategy for patients with HER2-overexpressing ovarian cancer, through ADCC effects. Therefore, this study supports a rationale for further clinical studies of the combination of samfenet and NK cells as a therapy for patients with HER2-overexpressing ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalTrastuzumabAntibody-Dependent Cell CytotoxicityOvarian NeoplasmsErb-b2 Receptor Tyrosine KinasesXenograft Model Antitumor AssaysFemaleHumansAnimalsMiceCell Line, TumorAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

ADCCHER2-overexpressed ovarian cancerNK celltrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalERBB2 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Science, The Graduate School, CHA University, Seongnam-si 13488, Republic of Korea.
  • Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, Republic of Korea.
  • Immunotherapy Team, New Biological Entity (NBE) Research, R&D Division, CHA Biotech, Seongnam-si 13488, Republic of Korea.
  • Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, Republic of Korea.
  • Division of Hematology-Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, Republic of Korea.

ORCID-Profile: Sa Deok Hong, Nar Bahadur Katuwal, Min Sil Kang, Seung Ryeol Lee, Yong Wha Moon

Förderung

  • National Research Foundation of Korea (NRF)

Zitieren

APA

Hong, S. D., Katuwal, N. B., Kang, M. S., Ghosh, M., Park, S. M., Kim, T. H., Baek, Y. S., Lee, S. R., & Moon, Y. W. (2024). Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111733

Vancouver

Hong SD, Katuwal NB, Kang MS, Ghosh M, Park SM, Kim TH, et al. Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111733

BibTeX
@article{Hong2024,
  author = {Hong, Sa Deok and Katuwal, Nar Bahadur and Kang, Min Sil and Ghosh, Mithun and Park, Seong Min and Kim, Tae Hoen and Baek, Young Seok and Lee, Seung Ryeol and Moon, Yong Wha},
  title = {Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252111733}
}
Kostenlos starten →